吡唑并[1,5-A]吡啶-3-甲酸乙酯 | 16205-44-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 中文名称: 吡唑并[1,5-A]吡啶-3-甲酸乙酯
• 中文别名: 吡唑并[1,5-a]吡啶-3-甲酸乙酯；吡唑并[1,5-α]吡啶-3-甲酸乙酯
• 英文名称: ethyl pyrazolo[1,5-a]pyridine-3-carboxylate
• 英文别名: pyrazolo[1,5-a]pyridine-3-carboxylic acid ethyl ester
• CAS: 16205-44-0
• 化学式: C₁₀H₁₀N₂O₂
• 分子量: 190.202
• InChiKey: IDHMFSBXNNIWCT-UHFFFAOYSA-N

物化性质

• 沸点：
  134-135°C/3mm
• 密度：
  1.23
• 闪点：
  134-135°C/2.3mm
• 稳定性/保质期：
  常温常压下稳定，避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R22,R36/37/38
• 海关编码：
  2933990090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  常温下应密闭避光保存，并保持干燥通风。

SDS

Name:	Ethyl pyrazolo[1 5-a]pyridine-3-carboxylate Material Safety Data Sheet
Synonym:	None know
CAS:	16205-44-0

Section 1 - Chemical Product MSDS Name:Ethyl pyrazolo[1 5-a]pyridine-3-carboxylate Material Safety Data Sheet
Synonym:None know

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
16205-44-0	Ethyl pyrazolo[1,5-a]pyridine-3-carbox	95+%	unlisted

Hazard Symbols: XN
Risk Phrases: 22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways.

---

Section 7 - HANDLING and STORAGE
Handling:
Use with adequate ventilation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 16205-44-0: Personal Protective Equipment Eyes: Wear chemical splash goggles.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Oil
Color: Yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H10N2O2
Molecular Weight: 190.2

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 16205-44-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl pyrazolo[1,5-a]pyridine-3-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 16205-44-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 16205-44-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 16205-44-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  吡唑并[1,5-A]吡啶-3-甲酸乙酯 在 硫酸 、 2,2,6,6-tetramethylpiperidinyl magnesium chloride-lithium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 3.25h， 生成 7-碘-吡唑并[1,5-A]吡啶
  参考文献：
  名称：

  使用Mg-和Zn-TMP碱基的吡唑并[1,5- a ]吡啶骨架的区域选择性金属化和功能化

  摘要：

  描述了在存在或不存在BF 3 ·OEt 2的情况下，使用Mg-和Zn-TMP碱基（TMP = 2,2,6,6-四甲基哌啶基）对吡唑并[1,5- a ]吡啶骨架进行的区域选择性官能化。另外，将具有酯官能团（和NHBoc或乙基）的各种官能化的吡唑并[1，5- a ]吡啶进行镁化和官能化，从而形成多取代的杂环。另外，据报道使用亚硫酸镁直接进行亚金属的邻位金属化，然后进行吡唑并[1，5- a ]吡啶亚砜的无过渡金属的胺化。

  DOI：

  10.1021/acs.orglett.8b01204
• 作为产物：
  描述：

  1-氨基吡啶碘 、 丙烯酸乙酯 在 氧气 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 24.0h， 以84%的产率得到吡唑并[1,5-A]吡啶-3-甲酸乙酯
  参考文献：
  名称：

  官能化吡唑并[1,5-a]吡啶的合成：N-氨基吡啶和α，β-不饱和羰基化合物/烯烃的[3 + 2]环加成反应在室温下

  摘要：

  摘要 描述了通过N-氨基吡啶与α，β-不饱和羰基化合物或吸电子烯烃的氧化[3 + 2]环加成反应，合成官能化的吡唑并[1,5- a ]吡啶。反应在室温下在无金属条件下在N-甲基吡咯烷酮作为溶剂中进行。 描述了通过N-氨基吡啶与α，β-不饱和羰基化合物或吸电子烯烃的氧化[3 + 2]环加成反应，合成官能化的吡唑并[1,5- a ]吡啶。反应在室温下在无金属条件下在N-甲基吡咯烷酮作为溶剂中进行。

  DOI：

  10.1055/s-0036-1588753

文献信息

• Optimized scale up of 3-pyrimidinylpyrazolo[1,5-a]pyridine via Suzuki coupling; a general method of accessing a range of 3-(hetero)arylpyrazolo[1,5-a]pyridines
  作者：Paul A. Bethel、Andrew D. Campbell、Frederick W. Goldberg、Paul D. Kemmitt、Gillian M. Lamont、Abid Suleman

  DOI：10.1016/j.tet.2012.04.094

  日期：2012.7

  an improved synthesis of 3-(hetero)aryl pyrazolo[1,5-a]pyridines (such as 3-(2,5-dichloropyrimidin-4-yl)pyrazolo[1,5-a]pyridine (8)) via an optimized synthesis and Suzuki coupling of 3-pyrazolo[1,5-a]pyridine boronic ester 10. These conditions are applicable to both high throughput chemistry and large scale synthesis of these medicinally important compounds. The scope of this chemistry has been further

  我们已经开发出3-（杂）芳基吡唑并[1,5- a ]吡啶（例如3-（2,5-二氯嘧啶-4-基）吡唑并[1,5- a ]吡啶（8）的合成方法。）通过优化的合成方法和3-pyrazolo [1,5- a ]吡啶硼酸酯10的Suzuki偶联。这些条件适用于这些医学上重要的化合物的高通量化学和大规模合成。该化学反应的范围已进一步扩展到包括新型硼酸酯3-（4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基）-6,7的合成和偶联-二氢-5 H-吡唑并[5,1- b ] [1,3]恶嗪（43）。
• [EN] PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIMIDIN-2-YLE UTILISÉS COMME INHIBITEURS DE JAK
  申请人：ALMIRALL SA

  公开号：WO2015086693A1

  公开（公告）日：2015-06-18

  New pyrazolopyridmiin-2-yl derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

  新的吡唑吡啶-2-基衍生物被披露；以及它们的制备方法，包含它们的药物组合物以及它们作为Janus激酶（JAK）抑制剂在治疗中的用途。
• [EN] VIRAL REPLICATION INHIBITORS<br/>[FR] INHIBITEURS DE REPLICATION VIRALE
  申请人：UNIV LEUVEN KATH

  公开号：WO2013045516A1

  公开（公告）日：2013-04-04

  The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

  本发明涉及一系列新化合物，通过使用这些新化合物来预防或治疗动物的病毒感染的方法，以及将这些新化合物用作药物，更好地用于治疗或预防病毒感染，特别是感染RNA病毒，更特别是感染属于黄病毒科的病毒，更特别是感染登革病毒。本发明还涉及这些新化合物的药物组合或混合制剂，用作药物的组合或制剂，更好地用于预防或治疗病毒感染。该发明还涉及这些化合物的制备方法。
• [EN] IMIDAZOTRIAZINONE COMPOUNDS<br/>[FR] COMPOSÉS D'IMIDAZOTRIAZINONE
  申请人：ENVIVO PHARMACEUTICALS INC

  公开号：WO2013142269A1

  公开（公告）日：2013-09-26

  The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

  本发明提供了咪唑三唑酮化合物，它们是磷酸二酯酶9的抑制剂及其药用盐。本发明还提供了用于治疗哺乳动物，包括人类，PDE9相关疾病或疾病的过程、药物组成、药物制剂和化合物的药用。
• 一种氮杂环二酮化合物及其制备方法
  申请人：维清生物科技(上海)有限公司

  公开号：CN111606928A

  公开（公告）日：2020-09-01

  本发明提供了一种氮杂环二酮化合物，其特征在于，为如下结构所示的化合物：该化合物对帽依赖性核酸内切酶抑有制活性。